SCOTUS extends emergency stay blocking mifepristone telemedicine ban

The Supreme Court extended a temporary stay on May 12, 2026, blocking a lower court ruling that would have reinstated in-person dispensing requirements for mifepristone, extending a protective legal stay while the appeal progresses. Justice Samuel Alito, acting as circuit justiceCircuit JusticeThe Supreme Court justice assigned to handle emergency matters from a specific federal circuit.Key ConceptCircuit JusticeThe Supreme Court justice assigned to handle emergency matters from a specific federal circuit.Open conceptBookmark for the 5th Circuit, issued the one-week extension through May 14 at 5 p.m. ET.

The legal fight began in October 2025 when Louisiana Attorney General Liz Murrill sued the FDA, arguing the agency's 2023 decision to allow telehealth prescriptions and mail-order delivery was arbitrary and capricious under the Administrative Procedure ActAdministrative Procedure Act1946 law governing how federal agencies develop regulations and make decisions through rulemaking and adjudication.Key ConceptAdministrative Procedure Act1946 law governing how federal agencies develop regulations and make decisions through rulemaking and adjudication.Open conceptBookmark, resulting in a 5th Circuit order that would have overwritten state-level protections for telehealth access in every state.

If the 5th Circuit's order takes effect, every patient in the United States would have to visit a certified clinic or hospital in person to obtain mifepristone. Drug manufacturers Danco Laboratories and GenBioPro warned the Supreme Court that such a sudden disruption would destabilize the federal regulatory framework for mail-order medications and jeopardize patient health.

Medication abortionMedication AbortionThe use of FDA-approved drugs — mifepristone and misoprostol — to end a pregnancy without surgery, now the most common abortion method in the United States.Key ConceptMedication AbortionThe use of FDA-approved drugs — mifepristone and misoprostol — to end a pregnancy without surgery, now the most common abortion method in the United States.Open conceptBookmark accounts for roughly 63% of all U.S. abortions, according to research on medication abortion provision following the 2022 Supreme Court ruling. The Society of Family Planning found that in the first half of 2025, more than 162,000 patients received mifepristone via telehealth, representing 27% of all clinician-provided abortions.

More than 30 amicus briefs were filed in the case, including one signed by former FDA commissioners from both Republican and Democratic administrations, warning that judicial substitution of clinical judgment threatens oncology and vaccine pipelines by exposing every drug approval to de novo review.

Disability rights organizations and abortion funds documented that an in-person requirement would fall disproportionately on low-income patients and those with disabilities, documenting that losing mail-order access eliminates the ability to obtain care entirely for those facing economic or physical barriers.

HHS Secretary Robert F. Kennedy Jr. commissioned a separate mifepristone safety review in September 2025, following a conservative think tank's assertions regarding the drug's safety record despite extensive peer-reviewed data showing serious complication rates below one-half percent.

The Supreme Court rejected a 2024 challenge to mifepristone because the plaintiffs, a group of physicians, could not demonstrate standing, with this case forcing the Court to confront whether the state's claims of direct Medicaid cost injury satisfied the constitutional standing threshold where previous challenges had failed.